News | June 07, 2022
MEI Pharma and Kyowa Kirin report new clinical data on Zandelisib
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
Operations at Oakville, Canada manufacturing plant expected to end by first quarter 2023
New Regional Processing Lab will serve Ahmedabad and the state of Gujarat
AstraZeneca also played a critical role in the global response to COVID-19.
The new Oncology CRO will aim to drive faster execution and higher quality trial outcomes for Oncology sponsors.
Focussed campaigns for old age homes, schools/colleges, prisons, brick kilns to be taken up by States/UTs
The product will be launched by NATCO's commercial partner Viatris.
The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
OS-SiA is the industry’s first AI-enabled digital scanner that will provide real-time predictive analysis and actionable insights
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
Subscribe To Our Newsletter & Stay Updated
